3,799 Shares in Colgate-Palmolive (NYSE:CL) Purchased by Legacy Private Trust Co.

Legacy Private Trust Co. bought a new position in shares of Colgate-Palmolive (NYSE:CL - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,799 shares of the company's stock, valued at approximately $356,000.

Other large investors also recently made changes to their positions in the company. Brighton Jones LLC lifted its stake in shares of Colgate-Palmolive by 4.4% during the fourth quarter. Brighton Jones LLC now owns 10,578 shares of the company's stock worth $962,000 after purchasing an additional 450 shares in the last quarter. Baader Bank Aktiengesellschaft lifted its position in Colgate-Palmolive by 50.3% during the 4th quarter. Baader Bank Aktiengesellschaft now owns 3,635 shares of the company's stock worth $330,000 after acquiring an additional 1,217 shares in the last quarter. Synergy Asset Management LLC acquired a new position in Colgate-Palmolive during the 4th quarter worth approximately $49,000. Crews Bank & Trust purchased a new position in Colgate-Palmolive in the 4th quarter worth approximately $73,000. Finally, Hamilton Point Investment Advisors LLC grew its position in Colgate-Palmolive by 3.9% in the fourth quarter. Hamilton Point Investment Advisors LLC now owns 50,804 shares of the company's stock valued at $4,619,000 after acquiring an additional 1,884 shares in the last quarter. Institutional investors and hedge funds own 80.41% of the company's stock.

Colgate-Palmolive Stock Performance

NYSE CL traded up $0.52 during trading hours on Wednesday, hitting $91.14. The company had a trading volume of 1,002,476 shares, compared to its average volume of 4,684,416. Colgate-Palmolive has a fifty-two week low of $85.32 and a fifty-two week high of $109.30. The firm has a market cap of $73.86 billion, a P/E ratio of 25.89, a price-to-earnings-growth ratio of 4.20 and a beta of 0.39. The company has a quick ratio of 0.58, a current ratio of 0.92 and a debt-to-equity ratio of 13.40. The business has a fifty day simple moving average of $91.97 and a 200-day simple moving average of $91.25.

Colgate-Palmolive (NYSE:CL - Get Free Report) last issued its quarterly earnings data on Friday, April 25th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.86 by $0.05. Colgate-Palmolive had a return on equity of 477.77% and a net margin of 14.38%. The business had revenue of $4.91 billion during the quarter, compared to the consensus estimate of $4.92 billion. During the same period in the previous year, the firm posted $0.86 earnings per share. The business's revenue was down 3.0% on a year-over-year basis. Equities analysts predict that Colgate-Palmolive will post 3.75 EPS for the current year.

Colgate-Palmolive Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 15th. Investors of record on Thursday, April 17th were paid a dividend of $0.52 per share. This is a boost from Colgate-Palmolive's previous quarterly dividend of $0.50. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.28%. The ex-dividend date was Thursday, April 17th. Colgate-Palmolive's payout ratio is currently 58.76%.

Colgate-Palmolive declared that its board has initiated a stock repurchase plan on Thursday, March 20th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. UBS Group upped their target price on shares of Colgate-Palmolive from $105.00 to $109.00 and gave the company a "buy" rating in a research note on Thursday, April 17th. JPMorgan Chase & Co. lifted their price objective on Colgate-Palmolive from $95.00 to $103.00 and gave the stock an "overweight" rating in a report on Monday, April 28th. Wall Street Zen cut Colgate-Palmolive from a "buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Barclays dropped their price target on shares of Colgate-Palmolive from $89.00 to $86.00 and set an "equal weight" rating for the company in a research note on Friday, April 11th. Finally, Piper Sandler dropped their target price on shares of Colgate-Palmolive from $108.00 to $107.00 and set an "overweight" rating for the company in a research report on Monday, March 31st. One analyst has rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, Colgate-Palmolive has an average rating of "Hold" and a consensus price target of $102.12.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.